Glucagon-like peptide-1 receptor agonist initiation and risk of clinically recorded Alzheimer's disease-type dementia in older adults with type 2 diabetes: a target trial emulation using causal machine learning
Journal:
medRxiv
Published Date:
Aug 24, 2026
Abstract
Background Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors are increasingly used for type 2 diabetes. Despite established metabolic, cardiovascular, and renal benefits, it remains uncertain whether GLP-1 receptor agonists are associated with longer clinically recorded Alzheimer's disease (AD)-type dementia-free survival than sulfonylureas (SU) or SGLT2 inhibitors. Methods Using All of Us electronic health records, we emulated target trials among adults aged 55 years or older with type 2 diabetes, a 12-month washout, and no prior dementia. We compared GLP-1 receptor agonists with SU and SGLT2 inhibitors. Propensity score weighting and doubly robust estimation addressed confounding. Causal survival forests estimated individualized treatment effects on 48-month RMST free from clinically recorded AD-type dementia. Findings In the GLP-1 receptor agonist versus SU comparison (6,328 individuals; 48-month NNT approximately 202), initiation was associated with a small but statistically significant increase in AD-type dementia-free survival (ATE 0.21 months; 95% CI: 0.07-0.35). The highest-benefit stratum gained 0.45 months (95% CI: 0.28-0.62). In the SGLT2 inhibitor comparison (3,070 individuals; 48-month NNT approximately 245), the average effect was not statistically significant (ATE 0.06 months; 95% CI: -0.18 to 0.31), but treatment effects were heterogeneous. The highest-benefit stratum gained 0.83 months (95% CI: 0.49-1.17). Predicted benefit was associated with older age, insulin use, lower HbA1c, and lower BMI. Interpretation GLP-1 receptor agonists may delay clinically recorded AD-type dementia compared with SU. Comparative effectiveness versus SGLT2 inhibitors may vary, supporting further study. Given the hypothesis-generating nature of these findings, diabetes treatment selection should remain guided by glycemic, cardiovascular, renal, and patient-centered considerations. Funding German Federal Ministry of Research, Technology and Space (03LWH0181B)
